Literature DB >> 3683759

Diagnostic difficulties in infantile neuroaxonal dystrophy. A clinicopathological study of eight cases.

V T Ramaekers1, B D Lake, B Harding, S Boyd, A Harden, E M Brett, J Wilson.   

Abstract

The clinical features of eight children with infantile neuroaxonal dystrophy are presented. Diagnosis was established by brain biopsy (4 cases), conjunctival biopsy (1 case), and the family history (2 cases), while in one case a presumptive diagnosis was made on the combination of clinical and neurophysiological findings without histopathological confirmation. The pleomorphic clinical picture and variable neurophysiological findings make a firm diagnosis difficult without histopathological confirmation. However, in the appropriate clinical context, serial neurophysiological investigations (ERG, VEP, EEG, ENMG) may suggest the diagnosis after the age of 2 years. Conjunctival biopsy is not invariably helpful, and neuroaxonal spheroïds are not always demonstrated in brain biopsies by conventional techniques. However, they were consistently identified using a non-specific esterase stain and by electron microscopy. This technique is described, and the significance of ultrastructural and neuropathological findings in infantile neuroaxonal dystrophy is discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3683759     DOI: 10.1055/s-2008-1052474

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  9 in total

Review 1.  Cerebral palsy: not always what it seems.

Authors:  R Gupta; R E Appleton
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

2.  Clinicopathological study of familial late infantile Hallervorden-Spatz disease: a particular form of neuroacanthocytosis.

Authors:  A Malandrini; G M Fabrizi; P Bartalucci; C Salvadori; G Berti; C Sabò; G C Guazzi
Journal:  Childs Nerv Syst       Date:  1996-03       Impact factor: 1.475

3.  Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations.

Authors:  Ibrahim Malik; John Turk; David J Mancuso; Laura Montier; Mary Wohltmann; David F Wozniak; Robert E Schmidt; Richard W Gross; Paul T Kotzbauer
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

Review 4.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

5.  Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.

Authors:  Laura A Engel; Zheng Jing; Daniel E O'Brien; Mengyang Sun; Paul T Kotzbauer
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

6.  Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden-Spatz disease and infantile neuroaxonal dystrophy.

Authors:  A Malandrini; T Cavallaro; G M Fabrizi; G Berti; R Salvestroni; C Salvadori; G C Guazzi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6.

Authors:  Haruka Wada; Takuwa Yasuda; Ikuo Miura; Kazuhiko Watabe; Chika Sawa; Hajime Kamijuku; Satoshi Kojo; Masaru Taniguchi; Ichizo Nishino; Shigeharu Wakana; Hisahiro Yoshida; Ken-ichiro Seino
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 8.  Disorders of metal metabolism.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-12-18

9.  The natural history of infantile neuroaxonal dystrophy.

Authors:  Fadie D Altuame; Gretchen Foskett; Paldeep S Atwal; Sarah Endemann; Mark Midei; Peter Milner; Mustafa A Salih; Muddathir Hamad; Mohammad Al-Muhaizea; Mais Hashem; Fowzan S Alkuraya
Journal:  Orphanet J Rare Dis       Date:  2020-05-01       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.